This Phase 1 open-label trial aims to evaluate the effect of famotidine on the pharmacokinetics (PK), safety and tolerability of taletrectinib in healthy adult participants. To assess famotidine's impact on key PK parameters of taletrectinib and evaluate other PK parameters as well as safety endpoints.
The study design:
Part 1: Taletrectinib 600 mg administered under 2-hour fasting condition with three regimens: (Treatment A: Taletrectinib alone, Treatment B: Taletrectinib 2 h after single 40 mg famotidine. Treatment C: Taletrectinib dosed between two 20 mg famotidine doses).
Part 2: Taletrectinib 400 mg administered with standard low-fat meal, followed by either Treatment B or C of famotidine co-administration.
Inclusion Criteria:
The participant must voluntarily sign an Informed Consent Form (ICF) prior to any study-related procedures.
Participants are able to communicate well with Investigators and complete the study in accordance with the protocol.
Between the ages of 18 and 55 years (inclusive) at the time of signing the ICF.
Healthy adult participants (healthy refers to the status of no clinically relevant abnormalities identified through medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory examinations).
Body weight is greater than 50.0 kg at Screening and the body mass index (BMI) is between 19 and 26 kg/m2.
Males and/or females who meet any of the following criteria:
For all females of childbearing potential, a negative pregnancy test must be obtained within 1 day before the first dose of study drug. Female participants of non-childbearing potential must meet at least 1 of the following criteria:
Must agree to avoid strenuous exercise from 72 hours prior to dosing on Day 1 of Period 1 until the EOT/ET visit.
Able to sign the informed consent and to comply with the protocol.
Patients with adequate organ function meeting the following criteria:
Exclusion Criteria:
Evidence or history of clinically significant hematology, kidney, endocrine, lung, gastrointestinal, cardiovascular, liver, mental, neurological, or allergic diseases (including drug allergies, but not including untreated, asymptomatic seasonal allergies at the time of dosing).
According to the Investigator's judgment, there are clinically significant abnormal laboratory results (hematology, serum chemistry, coagulation, and urinalysis).
Any active or unstable medical condition as judged by the Investigator.
The Investigator believes that the participant may be at increased risk of eye disease or have a history of eye disease, such as glaucoma, retinal shedding, glass turbidity, moth disease,etc.
Impaired cardiac function including clinically significant arrhythmias or clinically significant abnormality including but not limited to any of the following at Screening and Admission,repeat testing is allowed for verification, at the discretion of the Investigator:
The 12-lead ECG shows that the QTc is >450 milliseconds (msec) or the QRS duration exceeds >120 msec. If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc and QRS values should be used to determine the participant's eligibility.
History of febrile illness within 5 days prior to the first dose of study drug.
Positive blood screen for human Hepatitis B virus surface antigen, hepati is C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody.
Pregnancy or lactation/breastfeeding.
Use of food or drugs that are known to be strong or moderate cytochrome P450 (CYP)3A4/5 inhibitors or inducers or to be P-glycoprotein inhibitors within 14 days prior to the first dose of study drug until the EOT/ET visit.
Consumption of Seville oranges or grapefruit-containing foods or beverages within 14 days prior to the first dose of study until the EOT/ET visit.
Participants who have used prescription or over-the-counter (OTC) medication (other than ≤2 g/day acetaminophen or ≤800 mg/day ibuprofen or allowed contraception methods), vitamins, or herbal remedies, within 2 weeks or 5 half-lives before study drug administration, whichever is longer.
Participants who have received live vaccines or attenuated vaccines within 28 days prior to the first dose of study drug until the EOT/ET visit.
Participants who have received any investigational drug, device, biologic, or other agent (within 60 days or 5 half-lives, whichever is longer) prior to study drug administration on Day 1.
Participants who are reluctant to stop consuming caffeinated or purine-containing foods (e.g., coffee, tea, cola, chocolate) from 72 hours prior to the first dose of study drug until the EOT/ET visit.
History of regular alcohol consumption exceeding 14 drinks/week (1 drink =12 ounces [360 mL] beer, or 5 ounces [150 mL] of wine, or 1.5 ounces [45 mL] of hard liquor), or participants who are unwilling to stop drinking alcohol from 72 hours prior to the first dose of study drug until the EOT/ET visit.
Use of tobacco- or nicotine-containing products ≥5 cigarettes per day, or participants who are unwilling/unable to stop tobacco- or nicotine-containing products from 72 hours prior to the first dose of study drug to the EOT/ET visit.
A positive urine drug screen.
A positive blood or breath test for alcohol.
Underwent major surgery within 6 months prior to the first dose of study drug.
Blood donation or blood loss within 3 months prior to the first dose of study drug of ≥400 mL.
Plasma donation within 30 days prior to the first dose of study drug.
Participants with gastrointestinal, liver, kidney disease, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion within 3 months prior to screening and during the Screening Period, or have a medical history of platelet reduction induced by heparin or heparin-induced thrombocytopenia.
Unwilling or unable to comply with the dietary or other guidelines described in this protocol.
Participants who are investigational site staff members directly involved in the conduct of the study or are their family members; site staff members otherwise supervised by the Investigator, or participants who are Nuvation Bio employees directly involved in the conduct of the study.
Venous access considered inadequate for PK sample collection; history or evidence of adverse symptoms associated with phlebotomy or blood donation.
The Investigator judges that the participant is not suitable to participate in the study.
qchen@shxh-centerlab.com18621617880
A single oral dose of taletrectinib 600 mg 2 hours after a meal (2-hour fast),on the morning of Part 1, Treatment A Day 1.
A single oral dose of famotidine 40mg administered with a meal on the morning of Part 1, Treatment B Day 1, and taletrectinib 600mg administered orally 2 hours later (2-hour fast).
A single oral dose of famotidine 20mg administered to each participant on the night of Day 1. On the morning of Day 2, 8 hours after the prior dose of famotidine, participants will eat a meal and then be administered taletrectinib 600mg after a 2-hour fast; a final single oral dose of famotidine 20mg will be administered 2 hours after the dose of taletrectinib.
A single oral dose of taletrectinib 400 mg dosed within 30 min (no longer than 1 hour) after a meal,on the morning of Part 2 Treatment A Day 1.
A single oral dose of 40 mg famotidine and 2 hours later, taletrectinib 400 mg will be dosed within 30 min (no longer than 1 hour) after a meal.
A single oral dose of 20 mg famotidine. On the morning of Day 2 of Part 2 Treatment C, taletrectinib 400 mg should be administered within 30 min and no longer than 1 hour after a meal, 10 hours after the famotidine dose from the prior evening; a final oral dose of 20 mg famotidine will be administrated 2 hours later.
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects
Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
A Study to Explore the Effect of Acid-reducing Agents